Sara Pusceddu
Overview
Explore the profile of Sara Pusceddu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
1193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sabella G, Centonze G, Maisonneuve P, Grillo F, Lagano V, Garzone G, et al.
J Pathol Clin Res
. 2025 Mar;
11(2):e70020.
PMID: 40047117
Pulmonary typical carcinoids (TCs) are uncommon, well-differentiated neuroendocrine tumors of the lung that do not exhibit necrosis and have fewer than two mitoses per 2 mm, as defined by the...
2.
Galvani L, Zappi A, Pusceddu S, Gelsomino F, La Salvia A, Oldani S, et al.
Endocrine
. 2025 Jan;
PMID: 39853630
Background: Lung neuroendocrine neoplasms (NENs) represent about 20% of all lung cancers. Few therapeutic options are available for atypical carcinoids (ACs). Single-agent temozolomide (TEM) is active in lung NENs, but...
3.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, et al.
Cancer Med
. 2024 Dec;
13(23):e70393.
PMID: 39618336
Background: The identification of actionable molecular targets of pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6-methylguanine-DNA methyltransferase (MGMT) silencing may occur in a subset of PAC...
4.
Cavalcoli F, Rausa E, Ferrari D, Rosa R, Maccauro M, Pusceddu S, et al.
Diagnostics (Basel)
. 2024 Sep;
14(17).
PMID: 39272666
Background: Rectal neuroendocrine tumors (rNENs) are rare, constituting 1-2% of rectal tumors, and are often asymptomatic, leading to challenges in early diagnosis. Current management guidelines recommend endoscopic resection for small...
5.
Maccauro M, Cuomo M, Bauckneht M, Bagnalasta M, Mazzaglia S, Scalorbi F, et al.
Eur J Nucl Med Mol Imaging
. 2024 Sep;
52(1):291-304.
PMID: 39235614
Purpose: In Peptide Receptor Radionuclide Therapy (PRRT) with [Lu]Lu-DOTATATE of gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) a question remains open about the potential benefits of personalised dosimetry. This observational prospective study...
6.
Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, et al.
Eur J Cancer
. 2024 Aug;
209:114276.
PMID: 39128186
Background: Metastatic Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors characterized by high morbidity and limited systemic treatment options, mainly based on radiometabolic treatments or chemotherapy. Based on the preclinical...
7.
Lagana M, Habra M, Remde H, Almeida M, Cosentini D, Pusceddu S, et al.
Eur J Cancer
. 2024 Jul;
208:114122.
PMID: 39047533
Metastatic pheochromocytomas and paragangliomas (PPGLs) are frequently associated with skeletal complications. Primary objective: to describe the frequency of adverse skeletal related events (SREs) in PPGL patients with bone metastases (BMs)....
8.
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, Pusceddu S, et al.
Eur J Cancer
. 2024 Jul;
208:114129.
PMID: 39002347
Background: Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy is currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies....
9.
Scalorbi F, Garanzini E, Calareso G, Marzi C, Di Rocco G, Argiroffi G, et al.
Sci Rep
. 2024 Jul;
14(1):15782.
PMID: 38982134
This study aims to assess the predictive capability of cylindrical Tumor Growth Rate (cTGR) in the prediction of early progression of well-differentiated gastro-entero-pancreatic tumours after Radio Ligand Therapy (RLT), compared...
10.
Corti F, Rossi R, Cafaro P, Passarella G, Turla A, Pusceddu S, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893145
Among neuroendocrine neoplasms (NENs), a non-negligible proportion (9-22%) is represented by sufferers of NENs of unknown primary origin (UPO), a poor prognostic group with largely unmet clinical needs. In the...